Latest News
Below is a selection of the latest articles and press releases covering the Resolution Therapeutics story
Resolution Therapeutics Appoints Bill Symonds to its Board of Directors
London, 20 April 2021 – Resolution Therapeutics announces the appointment of Bill Symonds as a Non-Executive Director of the Company.
Resolution Therapeutics Appoints Dr Amol Ketkar as Chief Development Officer
London, 30 June, 2022 – Resolution Therapeutics announces the appointment of Dr. Amol Ketkar, as Chief Development Officer.
Resolution Therapeutics and panCELLa Inc announce a Research Evaluation and Option Agreement to develop iPSC-derived macrophage cell therapy for inflammatory organ disease
London and Toronto, 5 April 2022 - Resolution Therapeutics partners with panCELLa to develop iPSC-derived macrophage cell therapy for inflammatory organ disease.
Resolution Therapeutics Announces a £10m Extended Series A Financing from Syncona Ltd
London, 5 April 2022 - Resolution Therapeutics announces a £10M Series A extension to broaden its research pipeline into allogeneic macrophages for the treatment of liver disease.
Resolution Therapeutics Strengthens its Team with Two New Appointments
London, 17 February 2022 – Resolution Therapeutics announces the strengthening of its senior management team with the appointments of Victor Dillard as VP Corporate Development and Lorna Peers as VP Finance.
Resolution Therapeutics Appoints Lisa Bright to its Board of Directors
London, 12 April 2021 – Resolution Therapeutics announces the appointment of Lisa Bright as a Non-Executive Director of the Company.
Resolution: Fighting fibrosis with macrophages
Macrophages are emerging as one of the hottest tools in the fight against cancer, but Resolution is targeting a new application for the cells: attacking fibrosis.
Resolution Therapeutics Announces a £26.6m Series A Financing from Syncona Ltd
London, 2 December 2020 - Resolution Therapeutics announces the completion of a £26.6m Series A financing from Syncona Ltd.